5National Committee for Clinical Laboratory Standard, 2002. Performance Standards for Antimicrobial Susceptibility Testing. NCCLS, Wayne, Pa.
6Rhomberg PR, Jones RN , MYSTIC Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials:report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis, 2003,47:365-372.
7Pfaller MA, Jones RN , MYSTIC Study Group. Antimicrobial susceptibility of inducible Amp C β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents, 2002,19:383-388.
8Sader HS, Biedenbach DJ ,Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis, 2003,47:361-364.
9Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and resistance patterns in Brazilian hospitals:summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, 2001,5:200-214.
10Rorner H. Flavobacterium meningosepticum[J]. Infect Control, 1984, 5: 237.
8Palleroni N J, Bradbury J F. Stenotrophomonas maltophilia, a new bacterial genus for Xanthomonas maltophilia[J]. Int J Syst Bacteriol, 1993, 43 : 606-609.
9Denton M, Kerr, K G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia [J]. Clin Microb Rev,1998, 11(1) : 57-80.
10Foster N F, Chang B J, Riley T V. Evaluation of a modified selective differential medium for the isolation of Stenotrophomonas maltophilia [J]. J Microbiological Methods, 2008 , 75: 153-155.
